The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review

References

• Mbhele N, Chimukangara B, Gordon MHIV-1. Integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. Int J Antimicrob Agents. 2021;57(5):106343. doi:10.1016/j.ijantimicag.2021.106343
   PubMed Web of Science ®Google Scholar
• World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. HIV treatment-interim guidance; 2018. Available from: http://apps.who.int/iris/bitstream/handle/10665/273632/WHO-CDS-HIV-18.18eng.pdf?ua=1.Accessed January 23, 2024.
   Google Scholar
• World Health Organization. WHO recommends dolutegravir as preferred HIV treatment option in all populations; 2023. Available from: https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations.Accessed. Accessed January 23, 2024.
   Google Scholar
• World Health Organization. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service, delivery and monitoring: recommendations for a public health approach; 2021. Available from: https://www.who.int/news/item/16-07-2021-who-publishes-new-consolidated-hiv-guidelines-for-prevention-treatment-service-delivery-monitoring. Accessed January 23, 2024.
   Google Scholar
• Zhao Y, Keene C, Griesel R, et al. AntiRetroviral therapy in second-line: investigating tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial. Wellcome Open Res. 2021;6:1–13. doi:10.12688/WELLCOMEOPENRES.16597.1
   PubMedGoogle Scholar
• Keene CM, Griesel R, Zhao Y, et al. Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen. AIDS. 2021;35(9):1423–1432. doi:10.1097/QAD.0000000000002936
   PubMed Web of Science ®Google Scholar
• HHS Panel on antiretroviral guidelines for adults and adolescents. guidelines for the use of antiretroviral agents in adults and adolescents with HIV; 2022. Available from: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv.Accessed January 23, 2024.
   Google Scholar
• Dravid A, Morkar D, Prasad D, et al. A phase IV study on safety, tolerability and efficacy of dolutegravir, lamivudine, and tenofovir disoproxil fumarate in treatment naive adult Indian patients living with HIV-1. Pragmatic Obs Res. 2022;13:75–84. doi:10.2147/por.s361907
   PubMed Web of Science ®Google Scholar
• Tongtong Y, Shenghua H, Yin W, et al. Effectiveness and safety of dolutegravir versus efavirenz-based antiviral regimen in people living with HIV-1 in Sichuan province of china: a real-world study. J Acquir Immune Defic Syndr. 2022;91(S1):S1–S7. doi:10.1097/QAI.0000000000003041
   PubMedGoogle Scholar
• Goodacre SW. An introduction to economic evaluation. Emerg Med J. 2002;19(3):198–201. doi:10.1136/emj.19.3.198
   PubMed Web of Science ®Google Scholar
• Hutubessy R, Chisholm D, Tan-Torres Edejer T, et al. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003;1(1):1–13. doi:10.1186/1478-7547-1-8
   PubMedGoogle Scholar
• Turner HC, Archer RA, Downey LE, et al. An introduction to the main types of economic evaluations used for informing priority setting and resource allocation in healthcare: key features, uses, and limitations. Front Public Health. 2021;9:1–17. doi:10.3389/fpubh.2021.722927
   Web of Science ®Google Scholar
• McCann NC, Horn TH, Hyle EP, Walensky RP. Costs in the United States, 2012–2018. JAMA Intern Med. 2020;180(4):601–603. doi:10.1001/jamainternmed.2019.7108
   PubMed Web of Science ®Google Scholar
• Jamieson L, Serenata C, Makhubele L, et al. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. AIDS. 2021;35(Supplement 2):S173–S182. doi:10.1097/QAD.0000000000003068
   PubMedGoogle Scholar
• Nickel K, Halfpenny NJA, Snedecor SJ, Punekar YS. Correction to: comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naive patients infected with HIV-1: an update on a systematic review and network meta-analysis (BMC Infectious Diseases. BMC Infect Dis. 2021;21(1):1–11. doi:10.1186/s12879-021-06016-8
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. CHEERS task force. consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013;16(2):e1–5. doi:10.1016/j.jval.2013.02.010
   PubMed Web of Science ®Google Scholar
• Del Pino R, Díez-Cirarda M, Ustarroz-aguirre I, et al. Costs and effects of telerehabilitation in neurological and cardiological diseases: a systematic review. Front Med. 2022; 9: doi:10.3389/fmed.2022.832229
   Web of Science ®Google Scholar
• Javan-Noughabi J, Rezapour A, Hajahmadi M, Alipour V. Cost-effectiveness of single-photon emission computed tomography for diagnosis of coronary artery disease: a systematic review of the key drivers and quality of published literature. Clin Epidemiol Glob Heal. 2019;7(3):389–395. doi:10.1016/j.cegh.2018.07.008
   Web of Science ®Google Scholar
• Zheng A, Kumarasamy N, Huang M, et al. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India. J Int Aids Soc. 2018; (3):e25085
   PubMed Web of Science ®Google Scholar
• Phillips AN, Cambiano V, Nakagawa F, et al. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. The Lancet HIV. 2018;5(3):e146–e154. doi:10.1016/S2352-3018(17)30190-X
   PubMed Web of Science ®Google Scholar
• Phillips AN, Venter F, Havlir D, et al. Risks and benefit of dolutegravir-based antiretroviral drug regimen in sub-Saharan Africa: a modelling study. Lancet HIV. 2019; 6(2):e116
   PubMed Web of Science ®Google Scholar
• Punekar YS, Guo N, Tremblay G, Piercy J, Holbrook T, Young B Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. Lancet HIV. 2018;5(3): e146
   PubMed Web of Science ®Google Scholar
• Phillips AN, Bansi-Matharu L, Venter F, et al. Updated assessment of risk and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. Lancet HIV. 2020; 7(3): e193–200.
   PubMed Web of Science ®Google Scholar
• Kim DD, Wilkinson CL, Pope EF, Chambers JD, Cohen JT, Neumann PJ. The influence of time horizon on results of cost-effectiveness analyses. Expert Rev Pharmacoecon Outcomes Res. 2017;17(6):615–623. doi:10.1080/14737167.2017.1331432
   PubMed Web of Science ®Google Scholar
• Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2. Value Heal. 2012;15(6):804–811. doi:10.1016/j.jval.2012.06.016
   PubMed Web of Science ®Google Scholar
• McCreesh N, Andrianakis I, Nsubuga RN, et al. Choice of time horizon critical in estimating costs and effects of changes to HIV programmes. PLoS One. 2018;13(5):1–10. doi:10.1371/journal.pone.0196480
   Web of Science ®Google Scholar
• Haacker M, Hallett TB, Atun R. On discount rates for economic evaluations in global health. Health Policy Plan. 2020;35(1):107–114. doi:10.1093/heapol/czz127
   PubMed Web of Science ®Google Scholar
• Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharm Pract. 2021;19(1):1–10. doi:10.18549/PharmPract.2021.1.2302
   Web of Science ®Google Scholar
• Jain R, Grabner M, Onukwugha E. Sensitivity analysis in cost-effectiveness studies: from guidelines to practice. Pharmacoeconomics. 2011;29(4):297–314. doi:10.2165/11584630-000000000-00000
   PubMed Web of Science ®Google Scholar
• Clinton Health Access Initiative. ARV market report. The state of the HIV market in low- and middle-income countries.2022; Available from https://chai19.wpenginepowered.com/wp-content/uploads/2022/12/2022-CHAI-HIV-Market-Report-12.8.22.pdf. Accessed June 23, 2023.
   Google Scholar
• Sim J, Hill A. Is pricing of dolutegravir equitable? A comparative analysis of price and country income level in 52 countries. J Virus Erad. 2018;4(4):230–237. doi:10.1016/S2055-6640(20
   PubMed Web of Science ®Google Scholar
• HIV. Rates by country; 2023.
   Google Scholar
• World Health Organization; 2023. Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/estimated-number-of-people--living-with-hiv. Accessed November 2023.
   Google Scholar
• Ademi Z, Kim H, Zomer E, Reid CM, Hollingsworth B, Liew D. Overview of pharmacoeconomic modelling methods. Br J Clin Pharmacol. 2013;75(4):944–950. doi:10.1111/j.1365-2125.2012.04421.x
   PubMed Web of Science ®Google Scholar